Author:
Alamrani Anfal Atallah S,Alsada Ali Mohamed S,Alruwaili Taif Naif R,Algoufi Jumanah Faisal I,Alghanmi Ammar Khalid S,Alwabel Abdulmajeed Hisham A,Alahmari Abdulaziz Nasser A,Alshahrani Abdullah Ayed A,Alhawiti Rahmah Mohammad M
Subject
Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Drug Discovery
Reference33 articles.
1. Niquet J, Baldwin R, Suchomelova L, Lumley L, Naylor D, Eavey R, et al. Benzodiazepine-refractory status epilepticus: pathophysiology and principles of treatment. Ann N Y Acad Sci. 2016;1378(1):166-73. doi:10.1111/nyas.13147
2. Farrukh MJ, Bakry MM, Hatah E, Jan TH. Association between complementary and alternative medicines (CAM) usage and self-perceived cognitive impairment among epilepsy patients. Arch. Pharma. Pract. 2020;11(2):124-9.
3. Knake S, Rosenow F, Vescovi M, Oertel WH, Mueller HH, Wirbatz A, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia. 2001;42(6):714-8.
4. Alyoubi RA, SB-Ped CS. Applying Experiential Learning Theory to Paediatric Post-Graduate Epilepsy Training. Int. J. Pharm. Res. Allied Sci. 2020,9(4):147-50.
5. Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci. 1997;17(19):7532-40.